Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1710072 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $39.75Day −1.49%Mkt cap $4.3B1Y +184.9%Off 52W high −17.9%Vol (1Y) 76.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,338 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.4% of sh out |
| Days to cover8.3d |
| 13F net flow (QoQ)−1.63% |
| Top-10 13F concentration59.7% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$176.0M |
| ROE−34.2% |
| ROIC−34.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+60.2% |
| 1Y+184.9% |
| 3Y+445.3% |
| 5Y+103.7% |
| Since incept. (ann.)+5.4% |
Total return through 2026-07-29 · series begins 2021-03-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.3% |
| Ann. volatility (3Y)81.6% |
| Sharpe (1Y)1.73 |
| Sharpe (3Y)1.10 |
| Max drawdown (1Y)−21.0% |
| Max drawdown (3Y)−68.8% |
| Beta (3Y vs SPY)0.69 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 15.5M | $489M | 14.42% | +0.0% |
| RA CAPITAL MANAGEMENT, L.P. | 10.4M | $328M | 9.69% | +0.0% |
| Paradigm Biocapital Advisors LP | 7.4M | $232M | 6.85% | +12.6% |
| BAKER BROS. ADVISORS LP | 6.6M | $207M | 6.11% | +0.0% |
| BlackRock, Inc. | 6.5M | $204M | 6.02% | −2.4% |
| JANUS HENDERSON GROUP PLC | 5.9M | $186M | 5.50% | +29.5% |
| NOVO HOLDINGS A/S | 5.3M | $169M | 4.97% | +0.0% |
| Driehaus Capital Management LLC | 4.5M | $141M | 4.16% | +6.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 110.4% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 10,134,013 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.46 | — | — | — |
| 2025-09-30 | 2025-11-06 | −$0.39 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$0.34 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.43 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
